Abstract: The present invention provides a crystal of a monovalent cation salt of 3-hydroxyisovaleric acid (hereinafter, referred to as HMB), which is excellent in solubility and easy to handle, and a process for producing the crystal. A crystal of a monovalent cation salt of HMB is precipitated in an aqueous HMB solution containing a monovalent cation-containing compound and having a pH of 4.0 to 9.0, and the crystal of a monovalent cation salt of HMB is thereafter collected from the aqueous solution.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced.

Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

Abstract: An object is to provide a method for producing a port that can shorten the time for production.

Abstract: When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).

Abstract: An applicator for medical-use liquids includes a handle having a hollow cylindrical member, a container incorporated in the cylindrical member, and a cleaving member of the container; and an applying section having an attachment plate of an application pad (integrally) fixed to a lower end of the cylindrical member to be an inclined cross section and the application pad fixed to the attachment plate. The attachment plate has a bank section formed thick at a peripheral edge, a base bottom section formed as a recess in a center, an inclined outflow hole opened inclinedly with respect to the base bottom section near the base bottom section center such that the solution flows out toward an attachment plate distal end direction, and a weir provided in an arcuate or crescent shape. A flow of the solution flowed out from the inclined outflow hole is reversed to flow backward by the weir.

Abstract: The present invention provides a lid cover (1) of a medicine container (2) for preventing a medicine, which is air-tightly stored in a medicine container (2) that has a lid portion (22) that can be pierced with a needle (33), from leaking to an outside space when the medicine is suctioned using a syringe (3) having the needle (33), the lid cover (1) including a peripheral wall portion (10) that can be mounted to the lid portion (22) so as to surround a piercing face of the lid portion (22) that is pierced with the needle (33) and a ceiling face portion (50) that is continuous with an upper portion of the peripheral wall portion (10), and can be pierced with the needle (33), wherein the peripheral wall portion (10) and the ceiling face portion (50) are made of an elastic material, and are configured to air-tightly store the piercing face such that the piercing face is not exposed to the outside space in a state where the peripheral wall portion (10) is mounted to the lid portion (22), while also forming a clos

Abstract: An object of the present invention to provide an antiadhesive material designed to have time-varying fluidity as it exhibits a gel form of high fluidity at the time of administration, and exhibits a gel form of low fluidity after it is administered to an incised and sutured site. A powdery antiadhesive material to be mixed with an aqueous solvent upon use containing alginic acid and/or a salt thereof, that is configured to be mixed with the aqueous solvent upon use so that the viscosity at 37° C. is less than or equal to 70 mPas·s at the time of 5 minutes after mixing with the aqueous solvent, and the viscosity at 37° C. is more than or equal to 120 mPas·s at the time of 60 minutes after mixing, will have high fluidity at the time of administration when it is mixed with an aqueous solvent upon use in a clinical scene, and have low fluidity after it is administered to an incised and sutured site, and thus is capable of satisfying both the excellent operability and the antiadhesive effect.

Abstract: A reduced-dissolved-oxygen-content drug solution produced by filling and sealing the drug solution in a drug solution container (15) formed of a plastic material having an oxygen permeability of not lower than 200 cm3/m2·24 h·atm at 25° C. at 60% RH within 12 hours after a steam sterilization process or a hot water sterilization process and having a steady-state oxygen permeability of not higher than 100 cm3/m2·24 h·atm at 25° C. at 60% RH, subjecting the drug solution container to the steam sterilization process or the hot water sterilization process, and storing the drug solution container in an environment having deoxidization means for reducing the dissolved oxygen concentration of the drug solution to not higher than 2 ppm when the oxygen permeability of the plastic material reaches the steady-state level.

Abstract: An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.

Abstract: An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation.

Abstract: An object is to provide a port that is capable of securely preventing pulling-out of a sealing plug from a port body. Provided is a port including: a sealing plug through which a hollow needle can be pierced; a port body having a hollow structure with the sealing plug disposed therein; and a pulling-out preventing member to be attached to the port body. The port body includes: a part to be sealed that has a tubular shape with a first end and a second end opposite to the first end, and is configured so that the sealing plug is sealingly inserted into the part to be sealed; a connection part that has a tubular shape, is continuous with the first end of the part to be sealed, and has an outer periphery connected to the bag body to be filled with a medical liquid; and a part to be fitted that is formed in any one of an inner peripheral surface of the part to be sealed, an outer peripheral surface of the part to be sealed, and the second end of the part to be sealed.

Abstract: An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.

Abstract: An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation.

Abstract: The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.